MDGL - Madrigal Pharmaceuticals, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 116.42 |
| Open | 116.82 |
| Bid | 99.01 x 1400 |
| Ask | 117.58 x 1100 |
| Day's Range | 110.37 - 117.14 |
| 52 Week Range | 56.82 - 127.25 |
| Volume | 232,307 |
| Avg. Volume | 237,223 |
| Market Cap | 1.79B |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.81 |
| Earnings Date | Aug 05, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 177.92 |
- Simply Wall St.
We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GuruFocus.com
After Drug Failure, Genfit's Cupboard Is Nearly Bare
Company’s high hopes for NASH drug stymied, providing opening for Intercept Pharma treatment Continue reading...
- Insider Monkey
Was The Smart Money Right About Madrigal Pharmaceuticals (MDGL)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., May 07, 2020 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and highlights: “Madrigal continued to.
- ACCESSWIRE
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) concerning possible breaches of fiduciary duty. To ...
- GlobeNewswire
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to.
- GuruFocus.com
FDA Decisions on 5 Drugs Expected in 2nd Quarter
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)?
If you own shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) then it's worth thinking about how it contributes to...
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
CONSHOHOCKEN, Pa., Feb. 26, 2020 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights:.
- TipRanks
Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes
The term 'buy when there's blood in the streets' was coined in the 18th century by Baron Rothchild. The contrarian act, as most investors know, is a preemptive call to load up on shares of downtrodden and badly performing companies that have recently taken a severe beating in the market but present the perfect timing to invest. While some investors automatically avoid underperforming names, the ones willing to take the risk can often receive handsome reward once the company at question executes a turnaround.Wall Street pros know the system well and are often on the lookout for such opportunities. With this in mind, We'll open up the TipRanks database and take a look at three beaten down stock which those in the know think are ripe for a trend reversal. We used TipRanks’ Stock Screener to get the lowdown, and we also noticed that currently all three boast Strong Buy consensus ratings from the Street. Let’s check them out.World Wrestling Entertainment (WWE)Talk about bloody and beaten down stocks leads us nicely into the first name on our list; World Wrestling Entertainment. In contrast to the S&P 500’s record breaking performance last year, WWE lost almost 13% of its share price in 2019. The drop was reflected in WWE’s waning popularity – lower live attendances and TV ratings on top of less streaming subscribers are all worrying trends for the company.That’s the bad news, then. The good news is that WWE has taken care of TV revenue for the next 5 years. The company’s new US deal for its Raw and SmackDown programs should see it pocket in the region of $500 million annually over the period, which is approximately double what it made in the past year. Furthermore, its NXT brand brings in from Comcast an additional $30 million a year. With more international deals in place, the question is whether the company can turn around the declining figures to ensure its longevity once the current deals expire.Needham’s Laura Martin thinks WWE has what it takes. The 5-star analyst recently interviewed WWE’s management and came away confident in its prospects. Martin said, “WWE believes it can continue to grow US subs, even in the context of more fragmentation of audiences, suggesting that super-fandom niche OTT service are largely immune from the Streaming Wars between deep-pocketed general entertainment SVOD services. If true, this has positive implications for WWE's pricing power. Also, WWE uses social media and its linear TV air-time to lower its customer acquisition costs for its new OTT subscribers."Martin, therefore, reiterated her Buy rating on WWE. The 5-star analyst’s price target comes in at $88 and represents potential upside of 40%. (To watch Martin’s track record, click here)The Street agrees. A unanimous 10 Buy ratings dished out over the last 3 months presents WWE with a Strong Buy consensus rating. The average price target of $81.56 implies possible upside of 30%. (See WWE stock analysis on TipRanks)Ollie's Bargain Outlet (OLLI)Ollie's Bargain Outlet stock had quite a ride last year, increasing by over 50% before crashing back down whilst shedding 40% of its value. 2020 hasn’t kicked off all that well either; Ollie’s is down by nearly 18% year-to-date.The sell-off comes despite a better than expected F3Q19 report. Net sales of $327 million represented an improvement of 15.3% year-over-year and resulted in adjusted (non-GAAP) net income of $26.8 million, an increase of 28% over the same period in the prior year.Ollie’s has also been expanding opportunistically; last year the company bought 12 Toys R Us locations and leased six others around the country following the former toy giant’s bankruptcy. It also purchased almost $200 million dollars of toys from Toys R Us suppliers’ excess inventory.So, with Mr. Market being unkind to Ollie’s, should investors stay away? Not according to RBC analyst Scot Ciccarelli.The 5-star analyst believes the recent sell-off spells opportunity, noting, “We think Ollie’s has one of the best long-term store growth profiles in the Hardlines/Broadlines Retail sector. Further, the company’s stores generate strong cash-on-cash returns of ~60%+, with 4-wall EBITDA of $585,000–600,000 ($630,000 in most recent vintages) on an initial $1 million investment. In addition, its constantly changing/treasure hunt-oriented shopping experience, coupled with its steep clearance-level prices, should help insulate the company against e-commerce cannibalization.”Accordingly, Ciccarelli reiterated an Outperform rating on Ollie’s, while raising his price target from $69 to $76. The new price target represents possible gains in the shape of 42.5%. (To watch Ciccarelli’s track record, click here)Based on the consensus breakdown, the majority on the Street also back the discount retailer’s prospects in 2020. 4 Buys and a single hold assigned over the last 3 months amount to a Strong Buy consensus rating. At $72, the average price target presents possible upside of ~36%. (See OLLI stock analysis on TipRanks)Madrigal Pharmaceuticals Inc (MDGL)Completing our trio of beaten down stocks is Madrigal Pharmaceuticals, which saw its shares falling nearly 20% in 2019.In mid-December, the drugmaker's shares responded negatively to the announcement that a few investment funds affiliated with Bay City Capital are heading for the exits. The funds offered 1,200,000 Madrigal shares at $107.85 apiece -- a 9% discount to the previous closing price. In other words, the funds probably had to price the offering at a discount simply to entice investors.But things aren’t as bad as they may seem, argues Evercore analyst Joshua Schimmer.Madrigal is one of several companies hoping to bring a therapy for NASH disease (Non-Alcoholic SteatoHepatitis), a fatty liver disease that due to the obesity epidemic has been attracting lots of investment capital in search of a possible treatment. NASH medications are expected to increase into a massive market over the next decade, and as there are currently no NASH-specific drugs available, whoever brings a viable solution to the market will likely be well rewarded.Madrigal's lead drug candidate is resmetirom (MGL-3196), an orally administered, thyroid hormone receptor (THR) β-selective agonist. The drug is currently in a Phase 3 trial, after showing positive data in the 2 prior trials.Schimmer thinks “2020 is an execution year” for Madrigal. The 5-star analyst said, “We continue to believe that resmetirom may have a differentiated profile, as a clean, oral therapy… the company’s P2 dataset continues to stack up well to the competition which has seen multiple recent disappointments in the field. We continue to believe that resmetirom (MGL-3196) has a strong chance of success in P3, with results expected in ~2021.”To this end, Schimmer reiterated an Outperform rating on Madrigal along with a price target of $250. This implies upside potential of a massive 192%. (To watch Schimmer’s track record, click here)On the Street, Madrigal’s Strong Buy consensus rating breaks down into 6 Buys and 1 Hold. The average price target of $169.67 implies upside potential in the shape of 100% over the next 12 months. (See Madrigal stock analysis on TipRanks)
- Insider Monkey
Madrigal Pharmaceuticals, Inc. (MDGL): Hedge Fund Sentiment Unchanged
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
Madrigal Pharmaceuticals, Inc. (MDGL) announced today that it has dosed the first patient in its second Phase 3 clinical trial, MAESTRO-NAFLD-1 with its first-in-class, once daily, oral thyroid hormone receptor-beta selective agonist, resmetirom (MGL-3196). Madrigal initiated its first Phase 3 clinical program, MAESTRO-NASH, in NASH patients with advanced liver fibrosis (stages F2 and F3) in March 2019.
- American City Business Journals
Madrigal Pharmaceuticals investor selling large chunk of its stake
Investment funds affiliated with San Francisco-based Bay City Capital are selling about a quarter of their stake in Madrigal Pharmaceuticals, a West Conshohocken biopharmaceutical company developing treatment for cardiovascular, metabolic, and liver diseases. The investment funds, according to federal documents, expect to make $129.4 million by selling 1.2 million shares of Madrigal common stock at $107.85 per share.
- GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
In connection with the offering, the selling stockholders have granted the underwriter an option, exercisable for 30 days after December 10, 2019, to purchase up to 180,000 additional shares of common stock, at the public offering price, less underwriting discounts, from the selling stockholders. The offering is expected to close on or about December 13, 2019, subject to the satisfaction of customary closing conditions.
- GlobeNewswire
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
CONSHOHOCKEN, Pa., Dec. 10, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the.
- Zacks
NASH Scorecard Year to Date: The Winners and the Losers
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
- GlobeNewswire
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted.
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., Nov. 06, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: “Madrigal continued.
- Insider Monkey
Hedge Funds Are Dumping Madrigal Pharmaceuticals, Inc. (MDGL)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- GlobeNewswire
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal.
- GlobeNewswire
Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
Madrigal Pharmaceuticals, Inc. (MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President of Research & Development. Dr. Taub has served as Chief Medical Officer and Executive Vice President of Research & Development, of Madrigal since 2016.
- Simply Wall St.
Have Insiders Been Buying Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit.
- Insider Monkey
Here’s What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
GuruFocus.com2 Falling Knives With No Debt
Warning! GuruFocus has detected 3 Warning Signs with IRDM. The risk is very high with this kind of investment, but if investors look for companies that have no debt and a moderate to high current ratio, the risk can be significantly decreased. In addition, the companies have received an overweight recommendation rating from Wall Street, increasing the chances of a successful bet as these stocks are expected to outperform their industries within 12 months.
